{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:38:30Z","timestamp":1791639510011,"version":"4.3.4"},"reference-count":33,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,1]]},"abstract":"\n Context:<\/jats:title>\n Approximately 50 000 adults in the United States are diagnosed with GH deficiency, which has negative impacts on cognitive functioning, psychological well-being, and quality of life.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n This paper presents development and validation of a patient-reported outcome measure (PRO), the Treatment-Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD). The TRIM-AGHD was developed to measure the impact of GH deficiency and its treatment.<\/jats:p>\n <\/jats:sec>\n \n Design and Settings:<\/jats:title>\n The development and validation of the TRIM-AGHD was conducted according to the Food and Drug Administration guidance on the development of PROs. Concept elicitation, conducted in three countries included interviews with patients, clinical experts, and literature review. Qualitative data were analyzed based on grounded theory principles, and draft items were cognitively debriefed. The measure underwent psychometric validation in a US clinic-based population. An a priori statistical analysis plan included assessment of the measurement model, reliability, and validity. Item functioning was reviewed using item response theory analyses.<\/jats:p>\n <\/jats:sec>\n \n Patients or Other Participants:<\/jats:title>\n Forty-eight patients and six clinical experts participated in concept elicitation and 169 patients completed the validation study.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome Measure:<\/jats:title>\n TRIM-AGHD was measured.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Factor analysis resulted in four domains: energy level, physical health, emotional health, and cognitive ability. The item response theory confirmed adequate item fit and placement within their domain. Internal consistency ranged from 0.82 to 0.95 and test-retest ranged from 0.80 to 0.92. All prespecified hypotheses for convergent validity and all but two for discriminant validity were met.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n The final 26-item TRIM-AGHD can be considered a reliable and valid PRO of the impact of disease and treatment for adult GH deficiency.<\/jats:p>\n <\/jats:sec>","DOI":"10.1210\/jc.2013-3438","type":"journal-article","created":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T17:50:56Z","timestamp":1389981056000},"page":"1204-1212","source":"Crossref","is-referenced-by-count":11,"title":["Assessing the Impact of Growth Hormone Deficiency and Treatment in Adults: Development of a New Disease-Specific Measure"],"prefix":"10.1210","volume":"99","author":[{"given":"Meryl","family":"Brod","sequence":"first","affiliation":[{"name":"The Brod Group (M.B.), Mill Valley, California 94941;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"H\u00f8jbjerre","sequence":"first","affiliation":[{"name":"Department of Global Development (L.H., J.E.A., M.H.R.), Novo Nordisk A\/S, DK-2860 S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan Erpur","family":"Adalsteinsson","sequence":"first","affiliation":[{"name":"Department of Global Development (L.H., J.E.A., M.H.R.), Novo Nordisk A\/S, DK-2860 S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H\u00f8jby","family":"Rasmussen","sequence":"first","affiliation":[{"name":"Department of Global Development (L.H., J.E.A., M.H.R.), Novo Nordisk A\/S, DK-2860 S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"issue":"5","key":"2020071612575144400_B1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2265.1992.tb02347.x","article-title":"The growth hormone deficiency syndrome in adults","volume":"37","author":"Cuneo","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612575144400_B2","unstructured":"The Human Growth Foundation. Adult growth hormone deficiency explained. 2013. http:\/\/www.hgfound.org\/res_aghd.explained.asp. Accessed April 11, 2013."},{"issue":"2","key":"2020071612575144400_B3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1210\/jcem.83.2.4594","article-title":"Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee","volume":"83","author":"Carroll","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071612575144400_B4","first-page":"1671","article-title":"Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses","volume":"77","author":"Amato","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2020071612575144400_B5","first-page":"279","article-title":"Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency","volume":"84","author":"Janssen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2020071612575144400_B6","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.2003-030761","article-title":"Adults with partial growth hormone deficiency have an adverse body composition","volume":"89","author":"Murray","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612575144400_B7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1651-2227.1989.tb11249.x","article-title":"Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency","volume":"356","author":"McGauley","year":"1989","journal-title":"Acta Paediatr Scand Suppl"},{"issue":"9","key":"2020071612575144400_B8","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1210\/jc.2002-021792","article-title":"Decreased quality of life in adult patients with growth hormone deficiency compared with general populations using the new, validated, self-weighted questionnaire, questions on life satisfaction hypopituitarism module","volume":"88","author":"Blum","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2020071612575144400_B9","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/jcem.80.12.8530603","article-title":"Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial","volume":"80","author":"Burman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2020071612575144400_B10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2265.1994.tb02452.x","article-title":"Decreased psychological well-being in adult patients with growth hormone deficiency","volume":"40","author":"Rosen","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2020071612575144400_B11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2265.1996.704523.x","article-title":"The development, reliability and validity of a disease specific quality of life model for adults with growth hormone deficiency","volume":"44","author":"Wallymahmed","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2020071612575144400_B12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000012276","article-title":"Quality of life and cognitive function in patients with pituitary insufficiency","volume":"67","author":"Burman","year":"1998","journal-title":"Psychother Psychosom"},{"issue":"3","key":"2020071612575144400_B13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0306-4530(95)00050-X","article-title":"Cognitive impairments and mood disturbances in growth hormone deficient men","volume":"21","author":"Deijen","year":"1996","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"2020071612575144400_B14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2265.2003.01799.x","article-title":"Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects","volume":"59","author":"Malik","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2020071612575144400_B15","first-page":"107","article-title":"The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults","volume":"83","author":"Cuneo","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2020071612575144400_B16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1510325","article-title":"Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life","volume":"151","author":"Mahajan","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2020071612575144400_B17","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0306-4530(02)00045-8","article-title":"Quality of life of growth hormone (GH) deficient young adults during discontinuation and restart of GH therapy","volume":"28","author":"Stouthart","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"2020071612575144400_B18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1046\/j.1365-2265.2003.01870.x","article-title":"Psychological effects of withdrawal of growth hormone therapy from adults with growth hormone deficiency","volume":"59","author":"McMillan","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2020071612575144400_B19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1008987922774","article-title":"The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency","volume":"8","author":"McKenna","year":"1999","journal-title":"Qual Life Res"},{"key":"2020071612575144400_B20","first-page":"FP32","article-title":"Assessing the impact of growth hormone deficiency in adults: the TRIM-AGHD","volume":"34","author":"Brod","year":"2013","journal-title":"Endocr Rev"},{"issue":"3","key":"2020071612575144400_B21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1530\/eje.0.1450255","article-title":"Development and psychometric properties of a disease-specific quality of life questionnaire for adult patients with growth hormone deficiency","volume":"145","author":"Herschbach","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"2020071612575144400_B22","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims","author":"United States Food and Drug Administration","year":"2009"},{"key":"2020071612575144400_B23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1477-7525-3-42","article-title":"Validation of a patient-administered questionnaire to measure the activity impairment experienced by women with uncomplicated urinary tract infection: the Activity Impairment Assessment (AIA)","volume":"3","author":"Wild","year":"2005","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2020071612575144400_B24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/10640260290081678","article-title":"Beyond body image as a trait: the development and validation of the Body Image States Scale","volume":"10","author":"Cash","year":"2002","journal-title":"Eat Disord"},{"issue":"3","key":"2020071612575144400_B25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/014662167700100306","article-title":"The CES-D Scale: a self-report depression scale for research in the general population","volume":"1","author":"Radloff","year":"1977","journal-title":"Appl Psychol Meas"},{"issue":"Pt 1","key":"2020071612575144400_B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.2044-8260.1982.tb01421.x","article-title":"The Cognitive Failures Questionnaire (CFQ) and its correlates","volume":"21","author":"Broadbent","year":"1982","journal-title":"Br J Clin Psychol"},{"issue":"6","key":"2020071612575144400_B27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0277-9536(91)90150-B","article-title":"The MOS social support survey","volume":"32","author":"Sherbourne","year":"1991","journal-title":"Soc Sci Med"},{"issue":"7","key":"2020071612575144400_B28","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0191-8869(01)00213-6","article-title":"The Oxford Happiness Questionnaire: a compact scale for the measurement of psychological well-being","volume":"33","author":"Hills","year":"2002","journal-title":"Pers Individ Dif"},{"key":"2020071612575144400_B29","first-page":"170","article-title":"The psychological general well-being (PGWB) index","volume-title":"Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies","author":"Dupuy","year":"1984"},{"issue":"2","key":"2020071612575144400_B30","first-page":"321","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"2020071612575144400_B31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"2020071612575144400_B32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"2020071612575144400_B33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00043764-200201000-00004","article-title":"Stanford presenteeism scale: health status and employee productivity","volume":"44","author":"Koopman","year":"2002","journal-title":"J Occup Environ Med"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/99\/4\/1204\/9046216\/jcem1204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/99\/4\/1204\/9046216\/jcem1204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T22:32:35Z","timestamp":1594938755000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/99\/4\/1204\/2537260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2013-3438","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,1]]}}}